Flotufolastat F 18 PET in Men With Very Low PSA Recurrence

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Massachusetts General Hospital
Study ID
NCT06862856
Status
Recruiting
Apply to this trial

Conditions

  • Prostate Cancer (Adenocarcinoma)
  • Prostate Specific Antigen

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Positron Emission Tomography (PET) — DIAGNOSTIC_TEST
    This is a PET scan with flotufolastat F 18 injection.

Study Details

The purpose of this study is to assess detection rate of flotufolastat F 18 positron emission tomography (PET) for low prostate specific antigen (PSA) recurrence of prostate cancer (PC) following radical prostatectomy.

Key Dates

Start date
May 20, 2025
Status verified
May 2026
Primary completion
Jan 16, 2026
Completion
Dec 1, 2026

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: Very Low Prostate Specific Antigen Recurrence
    Men \>18 years of age will undergo screening to confirm eligibility for this research study. Participants will receive a PET scan with flotufolastat F 18 injection on study visit 2.

Primary Outcome Measure

Detection Rate [ Time Frame: Periprocedural to date of detected lesion ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Dana Farber Cancer InstituteBostonMassachusetts02215
Jonathan Leeman, MD
[email protected]
617-732-6452
Massachusetts General HospitalBostonMassachusetts02114
Jason Efstathiou, MD, DPhil
[email protected]
617-726-5866

Find similar trials in Boston, MA

By research site
Dana Farber Cancer Institute· Boston, MAMassachusetts General Hospital· Boston, MA

Related Studies